Journal List > J Korean Thyroid Assoc > v.5(2) > 1056506

J Korean Thyroid Assoc. 2012 Nov;5(2):132-137. Korean.
Published online November 28, 2012.  https://doi.org/10.11106/jkta.2012.5.2.132
Copyright © 2012. the Korean Thyroid Association. All rights reserved.
Anaplastic Thyroid Carcinoma - a Therapeutic Dilemma
Hang-Seok Chang
Department of Surgery, Yonsei University College of Medicine, Thyroid Cancer Center, Gangnam Severance Hospital, Seoul, Korea.

Correspondence: Hang-Seok Chang, MD, PhD, FACS, Department of Surgery, Yonsei University College of Medicine, Thyroid Cancer Center, Gangnam Severance Hospital, 211, Eonju-ro, Gangnam-gu, Seoul 135-720, Korea. Tel: 82-2-2019-3376, Fax: 82-2-3462-5994, Email: surghsc@yuhs.ac
Received October 04, 2012; Accepted October 20, 2012.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Anaplastic thyroid carcinoma (ATC) is a rare type of malignancy of thyroid follicular cell origin. It is one of the most aggressive human cancers, and typically associated with a fatal prognosis. Most patients are presenting as locally advanced and systemically disseminated disease. A single mode of therapy, whether it is surgery, chemotherapy, or radiotherapy, fails to afford significantly favorable outcomes. While multimodality approaches may enhance the treatment response to a small degree, such implementations of these modalities are often impractical as many patients are of old age and are unable to tolerate the intensity of treatments. As in many other types of carcinomas, radical resection may be the mainstay of therapy for ATC, but surgery itself is seldom possible for this condition. Even with aggressive surgical therapy for those invasive ATCs, there is no evidence of decreased recurrence rates, while only the post-surgical morbidity rates increase. One chemotherapeutic agent that seems to demonstrate some effect against ATC is adriamycin, which is more effective when administered in combination, and is also known to act synergistically with radiotherapy. A commonly employed treatment modality is the combination therapy of adriamycin and cisplatin administration with hyperfractionated radiation therapy. Other chemotherapeutic agents proven to be effective are taxanes such as paclitaxel and docetaxel. Despite of disappointing result of conventional radiotherapy, however, hyperfractionated radiation therapy and combined chemotherapy has been suggested to improve survival rates by some institutions, while others disagree. The dismal results of conventional treatments for ATCs have stimulated the investigation for new therapeutic methods with improved outcome. There have been a number of trials of new materials or therapeutic methods. In recent studies, some trials were partially successful or promising in vitro or in vivo. The examples of these trials are; redifferentiation therapies, molecular targeted therapies, and some other miscellaneous methods. Although the observations may suggest that some of the methods may have a therapeutic effect on ATCs, or may act as an adjunct to other primary treatment modality, the efficacy and safety have not been ascertained yet in human trials, and further confirmation through in-depth studies are required.

Keywords: Anaplastic thyroid cancer; Multidisciplinary approach; Molecular targeted therapy

References
1. Ain KB. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 1999;16(1):64–69.
2. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 2005;46(6):759–764.
3. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13(4):453–464.
4. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79(3):564–573.
5. Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol 1996;40(5):953–958.
6. Rivera M, Sang C, Gerhard R, Ghossein R, Lin O. Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens. Acta Cytol 2010;54(5):668–672.
7. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103(7):1330–1335.
8. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma A study of 70 cases. Am J Clin Pathol 1985;83(2):135–158.
9. Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg 2007;31(5):969–977.
10. Abate EG, Smallridge RC. Managing anaplastic thyroid carcinoma. Expert Rev Endocrinol Metab 2011;6(6):793–809.
11. Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17(1):41–47.
12. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8(8):715–726.
13. American Joint Cancer Committee. AJCC Cancer Staging Manual. Chicago, IL, USA: AJCC; 2010.
14. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16(1):17–44.
15. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med 2010;31(2):215–226.
16. Wiseman SM, Loree TR, Rigual NR, Hicks WL Jr, Douglas WG, Anderson GR, et al. Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck 2003;25(8):662–670.
17. La Perle KM, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 2000;157(2):671–677.
18. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J Clin Endocrinol Metab 2002;87(1):370–379.
19. O'Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M. Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci 2010;179(1):9–15.
20. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93(1):278–284.
21. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010;20(7):697–706.
22. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y, et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 2004;14(12):1020–1029.
23. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59(8):1811–1815.
24. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66(2):321–330.
25. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91(12):2335–2342.
26. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998;22(7):725–730.
27. Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr Opin Otolaryngol Head Neck Surg 2011;19(2):113–118.
28. Lu WT, Lin JD, Huang HS, Chao TC. Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma? Otolaryngol Head Neck Surg 1998;118(5):728–731.
29. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2000;11(9):1083–1089.
30. Pushkarev VM, Starenki DV, Saenko VO, Tronko MD, Yamashita S. Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma. Exp Oncol 2011;33(1):24–27.
31. Satake S, Sugawara I, Watanabe M, Takami H. Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines. Cancer Lett 1997;116(1):33–39.
32. Sekiguchi M, Shiroko Y, Arai T, Kishino T, Sugawara I, Kusakabe T, et al. Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines. Biomed Pharmacother 2001;55(8):466–474.
33. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiother Oncol 2009;92(1):100–104.
34. Pudney D, Lau H, Ruether JD, Falck V. Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid 2007;17(12):1243–1250.
35. Ain KB, Egorin MJ, DeSimone PA. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid 2000;10(7):587–594.
36. Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M, et al. The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol 2010;40(6):596–599.
37. Tennvall J, Tallroth E, el Hassan A, Lundell G, Akerman M, Biorklund A, et al. Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol 1990;29(8):1025–1028.
38. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006;107(8):1786–1792.
39. Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Inoue H, Yabuta T, et al. Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg 2009;32(1):47–50.
40. Higashiyama T, Ito Y, Hirokawa M, Masuoka H, Yabuta T, Fukushima M, et al. Optimal surgical procedure for locally curative surgery in patients with anaplastic thyroid carcinoma: importance of preoperative ultrasonography. Endocr J 2010;57(9):763–769.
41. Kojic SL, Strugnell SS, Wiseman SM. Anaplastic thyroid cancer: a comprehensive review of novel therapy. Expert Rev Anticancer Ther 2011;11(3):387–402.
42. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007;117(4):674–679.
43. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12(2):600–607.
44. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 2005;4(4):632–640.
45. Hoffman SF, Guthrie TH Jr. Cerebral cysticercosis. South Med J 1975;68(1):105–108.
46. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65(9):3716–3725.
47. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, Jasser SA, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6(6):1785–1792.